双环醇片联合恩替卡韦胶囊治疗慢性乙型肝炎患者的效果分析OA
Analysis of Efficacy of Dicycloalcohol Tablet Combined with Entecavir Capsule in the Treatment of Patients with Chronic Hepatitis B
目的:分析慢性乙型肝炎患者应用双环醇片联合恩替卡韦胶囊治疗的效果.方法:选择 2022年 1月—2023年 10月新泰市人民医院收治的 136例慢性乙型肝炎患者为研究对象,按随机数字表法将其分为对照组和研究组,每组 68例.对照组采用恩替卡韦胶囊治疗,研究组在对照组基础上采用双环醇片治疗.比较两组的治疗效果、乙型肝炎病毒e抗原(HBeAg)及乙型肝炎病毒脱氧核糖核酸(HBV-DNA)水平,HBV-DNA转阴率、肝功能指标、肝纤维化指标、免疫功能指标及不良反应发生情况.结果:研究组的治疗总有效率 88.24%高于对照组的 75.00%,差异有统计学意义(P<0.05);治疗后,两组HBeAg和HBV-DNA水平均低于治疗前,且研究组均低于对照组,研究组HBV-DNA转阴率高于对照组,差异均有统计学意义(P<0.05);治疗后,两组丙氨酸转氨酶、天冬氨酸转氨酶和总胆红素水平均低于治疗前,且研究组均低于对照组,两组白蛋白水平均高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0.05);治疗后,两组透明质酸酶、层黏连蛋白、Ⅲ型前胶原、Ⅳ型胶原水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05);治疗后,两组CD 3+、CD 4+和CD 4+/CD 8+水平均高于治疗前,且研究组均高于对照组,两组CD 8+水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);研究组不良反应发生率为 14.71%,高于对照组的 11.76%,但两组比较,差异无统计学意义(P>0.05).结论:慢性乙型肝炎患者的治疗中应用恩替卡韦胶囊联合双环醇片,能够提高治疗效果和HBV-DNA转阴率,降低患者的HBeAg和HBV-DNA水平,改善肝功能、肝纤维化指标和免疫功能,且安全性良好.
Objective:To analyze the therapeutic effect of Dicycloalcohol Tablets combined with Entecavir Capsule in patients with chronic hepatitis B.Methods:A total of 136 patients with chronic hepatitis B treated in Xintai People's Hospital from January 2022 to October 2023 were selected as the study objects,and were divided into a control group and a study group according to random number table method,with 68 cases in each group.The control group was treated with Entecavir Capsules,and the study group was treated with Dicycloalcohol Tablets on the basis of the control group.The therapeutic effect,hepatitis B virus e antigen(HBeAg)and hepatitis B virus deoxyribonucleic acid(HBV-DNA)levels,the negative rate of HBV-DNA,liver function indexes,liver fibrosis indexes,immune function indexes and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 88.24%higher than 75.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of HBeAg and HBV-DNA in two groups were lower than before treatment,and the study group were lower than the control group,the negative rate of HBV-DNA in two groups were higher than before treatment,and the study group was higher than the control group,with statistical significances(P<0.05).After treatment,the levels of alanine aminotransferase,aspartate aminotransferase and total bilirubin in both groups were lower than before treatment,and the study group were lower than the control group,the level of albumin in both groups were higher than before treatment,and the study group was higher than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of hyaluronidase,laminin,type Ⅲ procollagen and type Ⅳ collagen in the two groups were lower than before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in both groups were higher than before treatment,and the study group were higher than the control group,the level of CD8+in both groups were lower than before treatment,and study group was lower than the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the study group was 14.71%,which was higher than 11.76%in the control group,but there was no significant difference between the two groups(P>0.05).Conclusion:In the treatment of chronic hepatitis B patients,Entecavir Capsule combined with Dicycloalcohol Tablets can improve the therapeutic effect and negative HBV-DNA conversion rate,reduce the levels of HBeAg and HBV-DNA,improve liver function,liver fibrosis indicators and immune function,and have good safety.
王刚
山东省新泰市人民医院感染性疾病科,山东 新泰 271200
临床医学
慢性乙型肝炎双环醇片恩替卡韦治疗效果肝功能肝纤维化指标
Chronic hepatitis BBicyclicalcohol tabletsEntecavirTherapeutic effectLiver functionLiver fibrosis index
《中国伤残医学》 2024 (017)
26-30 / 5
评论